Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
54 hedge funds and large institutions have $13.2M invested in Unity Biotechnology in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 26 closing their positions.
4,220% more call options, than puts
Call options by funds: $4.15M | Put options by funds: $96K
118% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 11
32.48% more ownership
Funds ownership: 4.35% → 36.84% (+32%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
25% less funds holding
Funds holding: 72 → 54 (-18)
45% less capital invested
Capital invested by funds: $24.1M → $13.2M (-$10.9M)
65% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFVM
Founders Fund V Management
San Francisco,
California
|
+$1.29M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$443K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$162K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$145K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$142K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.71M |
| 2 |
ACM
Altium Capital Management
New York
|
-$1.69M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$489K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$291K |
| 5 |
Millennium Management
New York
|
-$241K |
UBX Hedge Fund Activity: Q4 2022 in Review
54 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q4 2022, worth a combined $13.2M — down 45% from $24.1M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of UBX and 9 opened new positions — a net loss of 17 holders — while 11 trimmed existing stakes and 24 added.
The largest buyer was Founders Fund V Management, adding an estimated $1.29M. The largest seller was Alyeska Investment Group, cutting an estimated $1.71M.
- 54 institutional investors held Unity Biotechnology (UBX) as of Q4 2022, down from 72 in Q3 2022.
- Funds reported $13.2M of Unity Biotechnology stock for Q4 2022, down 45% quarter-over-quarter.
- 9 funds opened new Unity Biotechnology positions in Q4 2022 and 26 closed out, a net change of -17 holders.
- The largest Unity Biotechnology buyer in Q4 2022 was Founders Fund V Management, an estimated $1.29M added.
- The largest Unity Biotechnology seller in Q4 2022 was Alyeska Investment Group, an estimated $1.71M sold.
Based on aggregated 13F filings for Q4 2022.